- Open Access
α4-integrins control viral meningoencephalitis through differential recruitment of T helper cell subsets
- Veit Rothhammer†1,
- Andreas Muschaweckh†2,
- Georg Gasteiger3,
- Franziska Petermann1,
- Sylvia Heink1,
- Dirk H Busch4,
- Mathias Heikenwälder2,
- Bernhard Hemmer1, 5,
- Ingo Drexler6 and
- Thomas Korn1, 5Email author
© Rothhammer et al.; licensee BioMed Central Ltd. 2014
- Received: 25 February 2014
- Accepted: 26 February 2014
- Published: 7 March 2014
Natalizumab blocks α4-integrins and is a prototypic agent for a series of anti-inflammatory drugs that impair trafficking of immune cells into the CNS. However, modulation of the access of immune cells to the CNS is associated with impaired immune surveillance and detrimental viral infections of the CNS. Here, we explored the potency of cellular immune responses within the CNS to protect against viral encephalitis in mice with T cell conditional disruption of VLA-4 integrin (α4β1) expression.
While VLA-4 expression in virus specific Th1 cells is non-redundant for their ability to access the CNS, α4-integrin deficient Th17 cells enter the CNS compartment and generate an inflammatory milieu upon intrathecal vaccinia virus (VV) infection. However, in contrast to Th1 cells that can adopt direct cytotoxic properties, Th17 cells fail to clear the virus due to insufficient Eomes induced perforin-1 expression.
The quality of the intrathecal cellular antiviral response under conditions of impaired VLA-4 function jeopardizes host protection. Our functional in vivo data extend our mechanistic understanding of anti-viral immunity in the CNS and help to estimate the risk potential of upcoming therapeutic agents that target the trafficking of immune cells into distinct anatomical compartments.
- Th17 Cell
- Experimental Autoimmune Encephalomyelitis
- Vaccinia Virus
- Vaccinia Virus Infection
Autoimmune inflammation of the CNS in multiple sclerosis (MS) and its animal model, experimental autoimmune encephalomyelitis (EAE), is mediated by antigen specific Th1 and Th17 cells . For many years integrin targeted blocking of T helper cell trafficking into the CNS has appeared to be an attractive approach to treat immunopathology in MS . In particular, monoclonal antibodies (natalizumab) to the α4 subunit of the integrin VLA-4 (α4β1 heterodimer) were successfully used to prevent the influx of immune cells into the CNS and to treat CNS autoimmunity . However, in experimental models it has been shown that distinct encephalitogenic T cell subsets vary in their equipment with VLA-4 . While Th1 cells maintain high amounts of VLA-4 expression, Th17 cells are low in VLA-4. As a consequence, blockade of VLA-4 is more efficient in preventing the recruitment of Th1 cells than of Th17 cells into the CNS parenchyma.
Although considered as an “immune privileged” organ, the CNS is still patrolled by T cells as a means of immune surveillance . The contribution of CD4+ vs CD8+ effector memory T cells in the migratory and resident pools of lymphocytes specific to a given pathogen has been investigated in skin infection but is unclear in the CNS . In the treatment of organ specific autoimmunity and chronic inflammation, efforts are increasing to market compounds that either inhibit immune cell trafficking [7–10] or cytokine networks that affect distinct T helper cell subsets in a differential manner (anti-IL-23p19, anti-IL-17A [11, 12], anti-GM-CSF (NCT01517282), anti-IL-6R ). However, preclinical models to investigate niche specific immune surveillance and host defense in the CNS are rare. Indeed, efalizumab, a blocking antibody to the integrin αL was withdrawn from the market in 2009 because of viral meningitis and cases of JC virus induced progressive multifocal leukencephalopathy (PML) .
Here, we established a CNS specific viral infection model that allowed us to analyze the contribution of distinct T helper cell subsets to host protection. We chose vaccinia virus (VV) infection where the importance of virus specific T helper cell responses has been analyzed previously [15, 16]. Vaccinated mice were found to be protected from intrathecal (i.th.) infection with VV due to cellular immunity. In the absence of CD8+ T cells, Th1 like cells were sufficient to protect mice from intrathecal VV infection. Access of Th1 cells into the infected CNS compartment was dependent on VLA-4 expression. Although virus specific Th17 cells were able to migrate into the CNS in the absence of VLA-4, CNS recruited and infected macrophages were not cleared by Th17 cells since Th17 cells – in contrast to Th1 cells – were deficient in perforin-1 expression. These data highlight a dominant role of Th1 cells in antiviral tissue-specific immunity. Our data further suggest that as in autoimmune inflammation of the CNS, virus specific Th1 cells are dependent on VLA-4 to enter into the CNS and virus infection does not overcome the requirement for Th1 cells to express VLA-4. Thus, integrin targeted therapeutic interventions in autoimmunity and chronic inflammation need to be refined in order to not jeopardize organ specific immune surveillance and host protection.
Animals, immunization, and infection
Foxp3gfp.KI mice [17, 18] and Itga4 flox/flox mice  have been described previously. CD4 Cre mice, Ifng -/- mice, Rag1 -/- mice, Prf1 -/- mice, and wild type C57BL/6 mice were obtained from Jackson Laboratories. CD45.1+ OT-II mice were kindly provided by DH Busch (Institute for Medical Microbiology, Immunology, and Hygiene, Technische Universität München). All mouse strains were on pure C57BL/6 background.
Mice were immunized by subcutaneous injection of 100 μl of an emulsion of 1 × 108 IU MVA or PBS in complete Freund’s adjuvant (CFA). For in vivo blockade of IFN-γ, mice were treated with every other day i.p. injections of a neutralizing antibody to IFN-γ (R4-6A2, BioXCell, West Lebanon, USA; 200 μg) or isotype control starting on day 9 after immunization. In a similar regimen, blocking antibodies to integrin α4 (PS/2, BioXCell, West Lebanon, USA; 200 μg), depleting antibodies to CD8 (YTS169.4, BioXcell; 200 μg) or CD4 (GK1.5, BioXcell; 200 μg) were administered every other day from day 9 or day 10 after immunization, respectively.
Intrathecal infection was performed as previously described . In brief, VV was inoculated into the cisterna magna of mice in deep anaesthesia by means of transcutaneous suboccipital puncture. Clinical signs of disease as well as weight loss in percent of initial weight (means + SEM) were monitored daily.
For adoptive transfer experiments, naïve T cells were isolated by magnetic sorting (CD4+CD62L+; T cell isolation kit II, mouse; Miltenyi Biotec, Germany) from CD45.1+ OT-II mice and differentiated in vitro into Th1 or Th17 cells. The differentiation status was checked on day 4 by intracellular cytokine staining and 2 × 106 cytokine positive T cells were injected i.v. into Rag1 -/- recipient mice, which had been infected with VV-Ova one day prior to T cell transfer.
Animals were kept in a specific pathogen-free facility at the Technische Universität München. All experimental protocols were approved by the standing committee for experimentation with laboratory animals of the Bavarian state authorities (“Governmental Department of Upper Bavaria, Approved animal experimental proposals No 55.2-1-54-2531-88-08 and No 55.2.1-54-2532-29-13 according to §8.1, German law for experimentation with laboratory animals”) and carried out in accordance with the corresponding guidelines.
Replication competent VV Western Reserve strain (VV) was provided by B Moss (National Institutes of Health, Bethesda, MD). Recombinant viruses encoding enhanced green fluorescent protein (VV eGFP) or full-length ovalbumin (VV-Ova) based on the Western Reserve strain were provided by JW Jewdell and JR Bennink (National Institutes of Health, Bethesda, MD). VV and replication deficient Modified Vaccinia Virus Ankara strain (MVA, cloned isolate IInew) used in this study were propagated and titered according to standard methodology .
T cell differentiation
Naïve T cells (CD4+CD62LhighCD25-) were isolated from lymph nodes and spleen by magnetic sorting (T cell isolation kit II, mouse; Miltenyi Biotec, Germany). Purity was in general higher than 95% as controlled by FACS staining. Naïve T cells were stimulated for 3 to 5 days with plate-bound antibody to CD3 (145-2C11, 4 μg/ml) and antibody to CD28 (PV-1, 2 μg/ml). Recombinant cytokines were added to the differentiation cultures as indicated: human TGF-β1 (2 ng/ml) and mouse IL-6 (50 ng/ml) for Th17, mouse IL-12 (10 ng/ml) and anti-IL-4 (10 μg/ml) for Th1, all R&D Systems.
Preparation of splenic and CNS mononuclear cells and antibody staining
Mononuclear cells were isolated from either spleen or CNS at the peak of disease (d4-d5 after intrathecal challenge). After perfusion through the left cardiac ventricle with cold PBS, the brain including cerebellum was dissected and the spinal cord flushed out with PBS by hydrostatic pressure. CNS tissue was digested with collagenase D (2.5 mg/ml, Roche Diagnostics, Indianapolis IN) and DNAseI (1 mg/ml, Sigma, Saint Louis, MO) at 37°C for 45 min. Mononuclear cells were isolated by passing the tissue through a cell strainer (70 μm) and percoll gradient (37% over 70%) centrifugation. Mononuclear cells were removed from the interphase, washed and resuspended in culture medium for further analysis. For isolation of mononuclear cells from spleen, spleens were mashed through a cell strainer (70 μm) and red blood cells were removed using BD Pharm Lyse (BD Biosciences). Surface staining of T cells was carried out with antibodies to CD3 (14-2C11), CD4 (RM4-5), CD8 (53-6.7), CD11b (M1/70), CD25 (PC61 or 7D4), CD44 (IM7), CD45 (30-F11) and Nk1.1 (PK136). All antibodies were purchased from BD Biosciences. Fluorescence-labeled MHC class I H-2Kb/B8R20-27 (TSYKFESV) multimers were provided by DH Busch.
Intracellular cytokine staining
Cells were stimulated in culture medium containing phorbol 12-myristate 13-acetate (PMA, 50 ng/ml, Sigma), ionomycin (1 μg/ml, Sigma), and monensin (GolgiStop 1 μl/ml, BD Biosciences) at 37°C and 10% CO2 for 4 hours. After staining of surface markers, cells were fixed and permeabilized (Cytofix/Cytoperm and Perm/Wash buffer, BD Biosciences) followed by staining with monoclonal antibodies to mouse IL-2, IL-17, or IFN-γ (BD Biosciences) and flow cytometric analysis (CYAN, Beckmann/Coulter).
For detection of VV-infected cells or macrophages, paraformaldehyde (PFA) (4%) fixed and paraffin embedded CNS tissue sections were incubated with Bond Primary Antibody Diluent (Leica) containing either polyclonal rabbit anti-VV serum (1:1000; Quartett Immunodiagnostika & Vertriebs-GmbH, Berlin) or monoclonal antibodies against Mac-3 (1:750; M3/84) purchased from BD Pharmingen. IHC staining was performed on an automated Leica BOND-MAX instrument using Bond Polymer Refine Detection Solution for DAB. For detection of GFAP, PFA-fixed and paraffin-embedded CNS sections were incubated with Dako polyclonal rabbit anti-GFAP antibodies (Z0034; 1:13000) in Ventana buffer and staining was performed on a Ventana NexES IHC Slide Stainer using iVIEW DAB Detection Kit (Ventana). Images were taken using the Leica SCN400 slide scanner analysis software or were acquired on an Olympus BX53 Microscope (DP72 camera) using the cellSens 1.8 digital imaging software (Olympus).
Quantitative PCR analysis
For quantitative PCR, RNA was extracted from magnetic bead-purified or flow cytometry-sorted cells ex vivo or after in vitro differentiation using RNeasy columns (Qiagen, Valencia, CA). Complementary DNA was transcribed as recommended (Applied Biosystems, Foster City, CA) and used as template for quantitative PCR. Primer plus probe mixtures were obtained from Applied Biosystems. The Taqman analysis was performed on a StepOne system from Applied Biosystems. The gene expression was normalized to the expression of β-actin.
T cells were lysed and denatured using RiPA buffer (Sigma-Aldrich). The protein lysates were separated by SDS-PAGE in 4–12% NuPAGE Bis-Tris Mini gels and transferred to nitrocellulose membranes (Invitrogen). After blocking with 5% low-fat dry milk in TBS-T, membranes were incubated with primary antibodies to Prf-1 (ab7203, Abcam) and β-actin (Abcam) in blocking solution overnight at 4°C. Primary antibody binding was detected with HRP-conjugated secondary antibodies (Dianova). The signal was visualized by enhanced chemiluminescence (Novex ECL, Invitrogen).
Antigen specific proliferative and cytokine responses
For CD154 (CD40L) staining, spleens from MVA immunized CD4 Cre - × Itga4 flox/flox or CD4 Cre + × Itga4 flox/flox mice were dissected on day 10 after immunization. Single cell suspensions were prepared and cells were seeded on a 12 well flat-bottom plate at a density of 2 × 106 cells/well. Single cells were restimulated with a mixture of I-Ab-restricted VV peptides (A33R, B2R, B5R, L4R; 30 μg/ml each) for 6 hours in the presence of brefeldin A (5 μg/ml) during the last 3 hours of incubation followed by surface and intracellular staining for CD40L (CD154 (MR1), eBioscience) and cytokines as indicated. A33R116-130 (YQLFSDAKANCTAES), B2R46-60 (VKDKYMWCYSQVNKR), B5R46-60 (FTCDQGYHSSDPNAV) and L4R176-190 (ISKYAGINILNVYSP) were obtained from Biosyntan, Berlin.
Retroviral transduction of T cells
pMIG Eomes (GFP) and control pMIG (GFP) retroviral constructs were a kind gift from SL Reiner (University of Pennsylvania, Philadelphia, PA) and FJ Quintana (Harvard Medical School, Boston, MA). Phoenix-Eco cells (PMID: 18432682, a kind gift of H-M Jaeck, Erlangen) were transiently transfected with plasmids by calcium phosphate precipitation in the presence of 25 μM chloroquine (Sigma Aldrich). Retroviral supernatants were collected two days post transfection. T cells were transduced 24 hours post polyclonal in vitro activation of naïve sorted CD4+ T cells with TGF-β and IL-6 (Th17). Retroviral supernatant and 4 μg/ml polybrene (Merck Millipore) were added to the pre-committed Th17 cells and a spin transduction was performed (2000 rpm, RT, 1 hour). Cells were further cultured for 3 days in Th17 polarizing conditions before GFP expressing cells were purified by FACS sorting and subjected to quantitative PCR analysis.
CNS tissue was digested as described and single cell suspensions were obtained by passing digested CNS tissue through a 70-μm nylon filter. Pelleted cells were subjected to three freeze-thaw cycles (-80°C and 37°C) and sonicated three times for 1 min. Serial dilutions in RPMI-1640 medium containing 10% FCS were added in duplicates to 90% confluent RK-13 cells seeded in 6-well plates and incubated for 24 hours at 37°C. Plaques were counted after crystal violet staining.
Mouse serum samples were collected at day 10 post immunization (MVA/CFA or PBS/CFA). All serum samples were heat-inactivated at 56°C for 30 min prior to testing. Serum dilutions were incubated with 10,000 PFU of sucrose gradient purified VV eGFP for 1 hour at 37°C and 5% CO2 in a 96-well plate. RK-13 cells were added and infection (MOI = 0.1) was carried out over night at 37°C and 5% CO2. Cells were harvested, washed and fixed in 1% paraformaldehyde. Percentage of VV-infected cells was determined by measuring eGFP expression in flow cytometric analyses (CYAN, Beckmann/Coulter). The percentage of virus neutralization was defined as (1-[percentage of GFP-expressing cells]/[percentage of GFP-expressing cells in controls without serum]) × 100.
Statistical evaluations of cell frequency measurements and gene expression levels were performed with the unpaired Student’s t test. Two-tailed p values < 0.05 were considered significant. Weight scores are given as means ± SEM. Multiple comparisons were performed by two-way-ANOVA and Bonferroni post-testing.
Intrathecal vaccinia virus (VV) infection causes lethal encephalitis
Immunization with modified vaccinia virus (MVA) protects against VV encephalitis
Antibody mediated blockade of α4-integrins leads to relative enrichment of Th17 cells in the CNS
Th17 cells fail to clear cerebral VV infection
Similar to the murine system, neutralization of α4-integrins by natalizumab in humans mainly blocks CD4+ T cells from entering into the CNS compartment but spares CD8+ T cells [23, 24]. Yet, intracerebral reconstitution of CD4+ effector T helper cell responses has been proposed to be necessary for efficient clearance of various viruses from the CNS including JC virus . We wanted to dissect the essential features of an intracerebral T helper cell response that would be able to control viral infection. Thus, we combined a system of T cell conditional ablation of α4-integrin expression (CD4 Cre + x Itga4 flox/flox mice, α4 CKO mice) with antibody mediated depletion of CD8+ T cells in order to investigate the differential contribution of Th1 cells vs Th17 cells to host protection in CNS infection in the absence of CTLs. To exclude possible alterations in priming of antigen specific T helper cell responses in the peripheral immune compartment of α4 CKO mice, we compared the fractions of antigen specific T cells on day 10 after subcutaneous immunization with MVA/CFA in the spleens of CD4 Cre - x Itga4 flox/flox (wild type control) versus CD4 Cre + x Itga4 flox/flox (α4 CKO) mice (Additional file 1: Figure S1). Upon ex vivo restimulation with I-Ab restricted VV epitopes, the fractions of antigen specific (CD40L+) CD4+ T cells and their cytokine profile were similar in wild type vs α4 CKO mice. Moreover, the anti-VV neutralizing serum response was equally effective in both groups on day 10 after immunization (Additional file 1: Figure S1). Thus, sensitization for adaptive cellular immune responses against VV in draining lymph nodes and spleen was not impaired by the lack of α4-integrins on T cells.
Th17 cells fail to clear i.th. VV infection due to lack of perforin-1 expression
It was possible that the reduced capacity of Th17 cells to provide host protection in intrathecal VV infection was simply due to reduced availability of IFN-γ within the CNS compartment. In order to test this possibility, we neutralized IFN-γ by monoclonal antibodies in MVA immune and CD8+ T cell depleted wild type mice (Additional file 2: Figure S2). In this purely T helper cell dependent scenario, VV specific Th1 and Th17 cells were generated and had access to the VV challenged CNS. Notably, the mice recovered from VV encephalitis despite ablation of IFN-γ. Efficiency of IFN-γ blockade was documented by reduced levels of MHC class II expression on microglial cells in the CNS compartment (Additional file 2: Figure S2). These data suggested that IFN-γ was redundant as an effector molecule in the clearance of intrathecal VV infection and refuted the idea that diminished IFN-γ expression by Th17 cells was responsible for the failure to clear intracerebral VV infection.
In this study, we tested the concept that host defense against viral infections of the CNS requires distinct T helper cell subsets. We show that access inhibition to the CNS of selected T helper cell subsets by integrin targeted interventions results in the failure of host defense. Intrathecal infection with vaccinia virus (VV) was controlled in vaccinated mice when CD4+ and CD8+ T cells had access to the CNS compartment. Blockade of α4-integrins by neutralizing antibodies or T cell conditional disruption of α4-integrin expression did not prevent CTLs and Th17 cells from entering the CNS parenchyma while Th1 cells were blocked from migrating into the CNS. When CD8+ CTLs were depleted, host defense against intrathecal VV infection was still maintained as long as efficient Th1 like responses were operational within the CNS. In contrast, Th17 cells alone failed to rescue individuals from CNS infection despite a strong inflammatory response. Perforin-1 expression by T helper cells was required for clearance of intrathecal VV infection and Th17 cells failed to eliminate VV in the CNS due to lack of Eomes dependent Prf1 expression.
Adaptive cellular immune responses are necessary for the clearance of systemic VV infection. CD8+ T cells recognize epitopes from early antigens of VV but robust CD4+ T cell responses are also required for direct and indirect antiviral effects [27–30]. Niche restricted or organ specific infection may afford specific effector functions. For example, VV skin infection is contained and cleared by a temporally and spatially organized interaction of Ly6G+ innate immune cells and CD8+ CTLs . In the ovaries, clearance of VV correlates with the number of effector memory CTLs that are present in the ovaries of VV immunized mice before challenge with the virus . Here, we established an intrathecal infection model with VV and used this system as an in vivo surrogate to correlate the access of distinct T helper cell subsets with successful host defense. Intrathecal infection of naive wild type C57BL/6 mice with VV was lethal because adaptive antiviral immune responses did not develop upon i.th. infection alone although innate immune cells and in particular CD11b+CD45high monocytic cells were recruited to the infected CNS. Active immunization of mice with MVA in CFA prior to i.th. VV challenge protected the animals from lethal encephalitis. Protection was independent of neutralizing antibodies. However, access of VV specific Th1 cells into the CNS compartment was necessary and sufficient for host protection.
Migration of effector cells into the CNS is mediated by chemokine receptors and integrins. Several cytolytic and non-cytolytic viral infection models of the CNS were used to investigate principles of immune cell recruitment into the CNS. Depending on the viral agent, immune cell recruitment into the CNS cleared the pathogen or in addition, caused immunopathogenic tissue damage. CCR5 and CXCR3 were identified to be important for immune cell recruitment into the CNS in west nile or MHV and LCMV infection, respectively [32–35]. Chemotaxis of immune cells must be complemented by integrin mediated interaction with endothelial cells for the transmigration of immune cells across the blood brain barrier . Early work suggested that accumulation of antigen specific T cells in the CNS compartment of sindbis virus infected animals is mediated by engagement of LFA-1 but not VLA-4 . Using genetic tools, we have recently shown that distinct T helper cell subsets use distinct integrins to access the CNS compartment in autoimmune inflammation. The entry of Th17 cells into the subarachnoid space most likely requires CCR6 and LFA-1 but is independent of VLA-4 [4, 38]. In fact, Th17 cells express low levels of α4-integrins since TGF-β, which is required for Th17 cell commitment [17, 39, 40], inhibits the expression of α4-integrins . Interestingly, antigen specific CD8+ CTLs also migrated into the CNS independently of α4-integrins (both in α4-integrin antibody blockade and T cell conditional genetic disruption of Itga4). This is consistent with the observation that CD4+ T cell are preferentially reduced in CSF of natalizumab treated patients as compared with CD8+ T cells resulting in the reversion of the CSF CD4+/CD8+ ratio . Although one report suggested that CD8+ T cell influx into the CNS was prevented by a blocking antibody to α4-integrins in an intracerebral corona virus infection model, it is unlikely that the recruitment of antigen specific CTLs was assessed by Ifergan et al. since their model did not allow for active priming and activation of adaptive T cell responses in the systemic lymphoid compartment prior to intracerebral challenge . In contrast to Th17 cells, VLA-4 expression is indispensable and non-redundant for the capacity of antigen experienced Th1 cells to infiltrate into the subarachnoid space and the CNS compartment. Here, we provide evidence that MHC class II positive infected phagocytic cells in the CNS need to be cleared by Th1 cells in order to rescue mice from lethal encephalitis. Thus, MVA-immune T cell conditional α4 KO mice succumbed to intrathecal VV challenge because they failed to recruit Th1 cells into the CNS despite regular Th17 cell accumulation.
Antigen specific CD4+ T cells communicated with virus infected macrophages within the CNS parenchyma and only eliminated the infected cells when they were sufficient in perforin-1 expression. In ectromelia infection, a natural mouse pox infection, perforin-1 expression by CD4+ T cells is required to clear the pathogen, and CD4+ T cell mediated killing of hematopoietic MHC class II expressing infected target cells occurs in the draining lymph nodes, the liver, and the spleen . Direct cytotoxic effects of antigen specific CD4+ T cells were also reported in systemic VV infection . In our model, T cell conditional α4-integrin deficient mice behaved like perforin-1 deficient animals and succumbed to infection because perforin-1 expressing Th1 cells did not reach the CNS compartment in the absence of VLA-4. Like in EAE, the cytokine phenotype of T helper cells that entered into the CNS compartment in the absence of α4-integrin showed a Th17 profile . Th17 cells did not express perforin-1. Initial Th17 cell commitment is sensitive to IL-2 and high IL-2 concentrations inhibit Th17 differentiation . In contrast, IL-2 promotes the expression of granzyme B and perforin-1 and boosts cytotoxic capacity of CD4+ T cells . While the transcriptional control of granzyme B and perforin-1 has in part been investigated in CD8+ T cells , we found that perforin-1 expression in Th1 cells is associated with Eomes and overexpression of Eomes in Th17 cells partially reconstituted perforin-1 expression. Similar observations have been reported for Th2 cells that per se also lack perforin-1 , which correlates with their low cytotoxic efficacy. However, lack of perforin-1 expression in Th17 cells may not be the only mechanism to impair their antiviral capacity. For example, Th17 cells are able to mount a protective response in primary lung infection with influenza in IL-10 KO mice suggesting that Th17 cells are particularly susceptible to IL-10 mediated suppression . In addition, induction of prosurvival factors by Th17 cells may contribute to viral persistence in the CNS in Theiler’s virus infection . Conversely, it is possible that in some anatomical niches, Th17 cells may contribute to protective antiviral immune responses, e.g. by effective IL-17 mediated recruitment of neutrophils in lung infection . Also, IL-21, which is produced by Th17 cells, might have a role in the modulation of primary and recall CTL responses by increasing their proliferation and reducing their sensitivity to exhaustion . However, overall it is a more common scenario that antiviral Th17 responses fail to clear viral pathogens but rather drive deleterious immunopathology in the skin , in the cornea , and also in the CNS.
We have shown that blockade or genetic lack of α4-integrins on T cells selectively modulated the access of T helper cell subsets to the CNS. Preferential limitation of Th1 trafficking jeopardized host defense against intrathecal VV infection. Nevertheless, our experimental system has several limitations: First, i.th. inoculation of VV does not represent a natural route of CNS infection. Yet, immunization with virus antigens in CFA provides an efficient way to generate both an antigen specific Th1 and Th17 response in the secondary lymphoid tissue and to study their trafficking and effector functions upon i.th. challenge with a well characterized pathogen. Second, i.th. VV infection results in an acute encephalomyelitis, which causes rapid decay and death of infected animals; in contrast, JC virus induced PML is due to insufficient control of a latent virus infection of oligodendrocytes. However, the intracerebral anti-JC virus CD4+ T cell response contributes substantially to JCV control because efficient clearance of JC virus from the CNS after immune reconstitution by wash-out of natalizumab in MS patients with PML is associated with the re-occurrence of Th1 cells in the CNS .
Our experimental model provides a mechanistic explanation for insufficient virus control under conditions of altered T cell migration. Our data raise the concern that treatment of humans with compounds like natalizumab that interfere with T cell trafficking not only by quantitatively reducing the migration of T cells into the CNS but also by selectively targeting distinct T cell subsets may evoke serious deficiencies in cellular immune responses at privileged anatomical sites like the CNS. As a result, primary infections or unexpected reactivations of latent viruses may be facilitated.
The data sets supporting the results of this article are included within the article and its additional files.
TK is recipient of a Heisenberg award by the Deutsche Forschungsgemeinschaft (DFG, KO2964/3-2). This work was supported by SyNergy (Munich Cluster of Systems Neurology) and by other grants from the DFG (SFB1054/B06, TR128/A06, A07) as well as by intramural funding of the Klinikum rechts der Isar (KKF B11-11). MH was supported by the Helmholtz foundation.
- Domingues HS, Mues M, Lassmann H, Wekerle H, Krishnamoorthy G: Functional and pathogenic differences of Th1 and th17 cells in experimental autoimmune encephalomyelitis. PLoS One 2010, 5: e15531. doi:10.1371/journal.pone.0015531 10.1371/journal.pone.0015531View ArticlePubMedPubMed CentralGoogle Scholar
- Yednock TA, Cannon C, Fritz LC, Sanchez-Madrid F, Steinman L, Karin N: Prevention of experimental autoimmune encephalomyelitis by antibodies against alpha 4 beta 1 integrin. Nature 1992, 356: 63–66. doi:10.1038/356063a0 10.1038/356063a0View ArticlePubMedGoogle Scholar
- Polman CH, O’Connor PW, Havrdova E, Hutchinson M, Kappos L, Miller DH, Phillips JT, Lublin FD, Giovannoni G, Wajgt A, Toal M, Lynn F, Panzara MA, Sandrock AW, AFFIRM Investigators: A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 2006, 354: 899–910. doi:10.1056/NEJMoa044397 10.1056/NEJMoa044397View ArticlePubMedGoogle Scholar
- Rothhammer V, Heink S, Petermann F, Srivastava R, Claussen MC, Hemmer B, Korn T: Th17 lymphocytes traffic to the central nervous system independently of α4 integrin expression during EAE. J Exp Med 2011, 208: 2465–2476. doi:10.1084/jem.20110434 10.1084/jem.20110434View ArticlePubMedPubMed CentralGoogle Scholar
- Ransohoff RM, Engelhardt B: The anatomical and cellular basis of immune surveillance in the central nervous system. Nat Rev Immunol 2012, 12: 623–635. doi: 10.1038/nri3265 10.1038/nri3265View ArticlePubMedGoogle Scholar
- Gebhardt T, Whitney PG, Zaid A, Mackay LK, Brooks AG, Heath WR, Carbone FR, Mueller SN: Different patterns of peripheral migration by memory CD4+ and CD8+ T cells. Nature 2011, 477: 216–219. doi:10.1038/nature10339 10.1038/nature10339View ArticlePubMedGoogle Scholar
- Lebwohl M, Tyring SK, Hamilton TK, Toth D, Glazer S, Tawfik NH, Walicke P, Dummer W, Wang X, Garovoy MR, Pariser D, Efalizumab Study Group: A novel targeted T-cell modulator, efalizumab, for plaque psoriasis. N Engl J Med 2003, 349: 2004–2013. doi: 10.1056/NEJMoa030002 10.1056/NEJMoa030002View ArticlePubMedGoogle Scholar
- Kappos L, Radue E-W, O’Connor P, Polman C, Hohlfeld R, Calabresi P, Selmaj K, Agoropoulou C, Leyk M, Zhang-Auberson L, Burtin P, FREEDOMS Study Group: A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med 2010, 362: 387–401. doi: 10.1056/NEJMoa0909494 10.1056/NEJMoa0909494View ArticlePubMedGoogle Scholar
- Selmaj K, Li DK, Hartung H-P, Hemmer B, Kappos L, Freedman MS, Stüve O, Rieckmann P, Montalban X, Ziemssen T, Auberson LZ, Pohlmann H, Mercier F, Dahlke F, Wallström E: Siponimod for patients with relapsing-remitting multiple sclerosis (BOLD): an adaptive, dose-ranging, randomised, phase 2 study. Lancet Neurol 2013, 12: 756–767. doi:10.1016/S1474–4422(13)70102–9 10.1016/S1474-4422(13)70102-9View ArticlePubMedGoogle Scholar
- Miller DH, Weber T, Grove R, Wardell C, Horrigan J, Graff O, Atkinson G, Dua P, Yousry T, Macmanus D, Montalban X: Firategrast for relapsing remitting multiple sclerosis: a phase 2, randomised, double-blind, placebo-controlled trial. Lancet Neurol 2012, 11: 131–139. doi:10.1016/S1474–4422(11)70299-X 10.1016/S1474-4422(11)70299-XView ArticlePubMedGoogle Scholar
- Hueber W, Patel DD, Dryja T, Wright AM, Koroleva I, Bruin G, Antoni C, Draelos Z, Gold MH, Durez P, Tak PP, Gomez-Reino JJ, Foster CS, Kim RY, Samson CM, Falk NS, Chu DS, Callanan D, Nguyen QD, Rose K, Haider A, Di Padova F, Psoriasis Study Group: Effects of AIN457, a fully human antibody to interleukin-17A, on psoriasis, rheumatoid arthritis, and uveitis. Sci Transl Med 2010, 2: 52ra72. doi:10.1126/scitranslmed.3001107View ArticlePubMedGoogle Scholar
- Leonardi C, Matheson R, Zachariae C, Cameron G, Li L, Edson-Heredia E, Braun D, Banerjee S: Anti-interleukin-17 monoclonal antibody ixekizumab in chronic plaque psoriasis. N Engl J Med 2012, 366: 1190–1199. doi:10.1056/NEJMoa1109997 10.1056/NEJMoa1109997View ArticlePubMedGoogle Scholar
- Yazici Y, Curtis JR, Ince A, Baraf H, Malamet RL, Teng LL, Kavanaugh A: Efficacy of tocilizumab in patients with moderate to severe active rheumatoid arthritis and a previous inadequate response to disease-modifying antirheumatic drugs: the ROSE study. Ann Rheum Dis 2012, 71: 198–205. doi:10.1136/ard.2010.148700 10.1136/ard.2010.148700View ArticlePubMedGoogle Scholar
- Major EO: Progressive multifocal leukoencephalopathy in patients on immunomodulatory therapies. Annu Rev Med 2010, 61: 35–47. doi:10.1146/annurev.med.080708.082655 10.1146/annurev.med.080708.082655View ArticlePubMedGoogle Scholar
- Sette A, Moutaftsi M, Moyron-Quiroz J, McCausland MM, Davies DH, Johnston RJ, Peters B, Rafii-El-Idrissi Benhnia M, Hoffmann J, Su H-P, Singh K, Garboczi DN, Head S, Grey H, Felgner PL, Crotty S: Selective CD4+ T cell help for antibody responses to a large viral pathogen: deterministic linkage of specificities. Immunity 2008, 28: 847–858. doi:10.1016/j.immuni.2008.04.018 10.1016/j.immuni.2008.04.018View ArticlePubMedPubMed CentralGoogle Scholar
- Moutaftsi M, Bui H-H, Peters B, Sidney J, Salek-Ardakani S, Oseroff C, Pasquetto V, Crotty S, Croft M, Lefkowitz EJ, Grey H, Sette A: Vaccinia virus-specific CD4+ T cell responses target a set of antigens largely distinct from those targeted by CD8+ T cell responses. J Immunol 2012, 178: 6814–6820.View ArticleGoogle Scholar
- Bettelli E, Carrier Y, Gao W, Korn T, Strom TB, Oukka M, Weiner HL, Kuchroo VK: Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature 2006, 441: 235–238. doi:10.1038/nature04753 10.1038/nature04753View ArticlePubMedGoogle Scholar
- Korn T, Reddy J, Gao W, Bettelli E, Awasthi A, Petersen TR, Bäckström BT, Sobel RA, Wucherpfennig KW, Strom TB, Oukka M, Kuchroo VK: Myelin-specific regulatory T cells accumulate in the CNS but fail to control autoimmune inflammation. Nat Med 2007, 13: 423–431. doi:10.1038/nm1564 10.1038/nm1564View ArticlePubMedPubMed CentralGoogle Scholar
- Scott LM, Priestley GV, Papayannopoulou T: Deletion of alpha4 integrins from adult hematopoietic cells reveals roles in homeostasis, regeneration, and homing. Mol Cell Biol 2003, 23: 9349–9360. 10.1128/MCB.23.24.9349-9360.2003View ArticlePubMedPubMed CentralGoogle Scholar
- Koedel U, Rupprecht T, Angele B, Heesemann J, Wagner H, Pfister H-W, Kirschning CJ: MyD88 is required for mounting a robust host immune response to Streptococcus pneumoniae in the CNS. Brain 2004, 127: 1437–1445. doi:10.1093/brain/awh171 10.1093/brain/awh171View ArticlePubMedGoogle Scholar
- Staib C, Drexler I, Sutter G: Construction and isolation of recombinant MVA. Methods Mol Biol 2004, 269: 77–100. doi:10.1385/1–59259–789–0:077PubMedGoogle Scholar
- Hickman HD, Reynoso GV, Ngudiankama BF, Rubin EJ, Magadán JG, Cush SS, Gibbs J, Molon B, Bronte V, Bennink JR, Yewdell JW: Anatomically restricted synergistic antiviral activities of innate and adaptive immune cells in the skin. Cell Host Microbe 2013, 13: 155–168. doi:10.1016/j.chom.2013.01.004 10.1016/j.chom.2013.01.004View ArticlePubMedPubMed CentralGoogle Scholar
- Stüve O, Marra CM, Bar-Or A, Niino M, Cravens PD, Cepok S, Frohman EM, Phillips JT, Arendt G, Jerome KR, Cook L, Grand’Maison F, Hemmer B, Monson NL, Racke MK: Altered CD4+/CD8+ T-cell ratios in cerebrospinal fluid of natalizumab-treated patients with multiple sclerosis. Arch Neurol 2006, 63: 1383–1387. doi:10.1001/archneur.63.10.1383 10.1001/archneur.63.10.1383View ArticlePubMedGoogle Scholar
- Kowarik MC, Pellkofer HL, Cepok S, Korn T, Kümpfel T, Buck D, Hohlfeld R, Berthele A, Hemmer B: Differential effects of fingolimod (FTY720) on immune cells in the CSF and blood of patients with MS. Neurology 2011, 76: 1214–1221. doi:10.1212/WNL.0b013e3182143564 10.1212/WNL.0b013e3182143564View ArticlePubMedGoogle Scholar
- Jelcic I, Aly L, Binder TMC, Jelcic I, Bofill-Mas S, Planas R, Demina V, Eiermann TH, Weber T, Girones R, Sospedra M, Martin R: T cell epitope mapping of JC polyoma virus-encoded proteome reveals reduced T cell responses in HLA-DRB1*04:01+ donors. J Virol 2013, 87: 3393–3408. doi:10.1128/JVI.02803–12 10.1128/JVI.02803-12View ArticlePubMedPubMed CentralGoogle Scholar
- Eshima K, Chiba S, Suzuki H, Kokubo K, Kobayashi H, Iizuka M, Iwabuchi K, Shinohara N: Ectopic expression of a T-box transcription factor, eomesodermin, renders CD4(+) Th cells cytotoxic by activating both perforin- and FasL-pathways. Immunol Lett 2012, 144: 7–15. doi:10.1016/j.imlet.2012.02.013 10.1016/j.imlet.2012.02.013View ArticlePubMedGoogle Scholar
- Jellison ER, Kim S-K, Welsh RM: Cutting edge: MHC class II-restricted killing in vivo during viral infection. J Immunol 2005, 174: 614–618.View ArticlePubMedGoogle Scholar
- Fang M, Siciliano NA, Hersperger AR, Roscoe F, Hu A, Ma X, Shamsedeen AR, Eisenlohr LC, Sigal LJ: Perforin-dependent CD4+ T-cell cytotoxicity contributes to control a murine poxvirus infection. Proc Natl Acad Sci U S A 2012, 109: 9983–9988. doi:10.1073/pnas.1202143109/-/DCSupplemental 10.1073/pnas.1202143109View ArticlePubMedPubMed CentralGoogle Scholar
- Sun JC, Bevan MJ: Defective CD8 T cell memory following acute infection without CD4 T cell help. Science 2003, 300: 339–342. doi:10.1126/science.1083317 10.1126/science.1083317View ArticlePubMedPubMed CentralGoogle Scholar
- Xu R, Johnson AJ, Liggitt D, Bevan MJ: Cellular and humoral immunity against vaccinia virus infection of mice. J Immunol 2004, 172: 6265–6271.View ArticlePubMedGoogle Scholar
- Bachmann MF, Wolint P, Schwarz K, Oxenius A: Recall proliferation potential of memory CD8+ T cells and antiviral protection. J Immunol 2005, 175: 4677–4685.View ArticlePubMedGoogle Scholar
- Glass WG, Lim JK, Cholera R, Pletnev AG, Gao J-L, Murphy PM: Chemokine receptor CCR5 promotes leukocyte trafficking to the brain and survival in West Nile virus infection. J Exp Med 2005, 202: 1087–1098. doi:10.1084/jem.20042530 10.1084/jem.20042530View ArticlePubMedPubMed CentralGoogle Scholar
- Glass WG, Liu MT, Kuziel WA, Lane TE: Reduced macrophage infiltration and demyelination in mice lacking the chemokine receptor CCR5 following infection with a neurotropic coronavirus. Virology 2001, 288: 8–17. doi:10.1006/viro.2001.1050 10.1006/viro.2001.1050View ArticlePubMedGoogle Scholar
- Nansen A, Christensen JP, Andreasen SØ, Bartholdy C, Christensen JE, Thomsen AR: The role of CC chemokine receptor 5 in antiviral immunity. Blood 2002, 99: 1237–1245. 10.1182/blood.V99.4.1237View ArticlePubMedGoogle Scholar
- Christensen JE, Nansen A, Moos T, Lu B, Gerard C, Christensen JP, Thomsen AR: Efficient T-cell surveillance of the CNS requires expression of the CXC chemokine receptor 3. J Neurosci 2004, 24: 4849–4858. doi:10.1523/JNEUROSCI.0123–04.2004 10.1523/JNEUROSCI.0123-04.2004View ArticlePubMedGoogle Scholar
- Engelhardt B, Ransohoff RM: Capture, crawl, cross: the T cell code to breach the blood-brain barriers. Trends Immunol 2012, 33: 579–589. doi:10.1016/j.it.2012.07.004 10.1016/j.it.2012.07.004View ArticlePubMedGoogle Scholar
- Irani DN, Griffin DE: Regulation of lymphocyte homing into the brain during viral encephalitis at various stages of infection. J Immunol 1996, 156: 3850–3857.PubMedGoogle Scholar
- Reboldi A, Coisne C, Baumjohann D, Benvenuto F, Bottinelli D, Lira S, Uccelli A, Lanzavecchia A, Engelhardt B, Sallusto F: C-C chemokine receptor 6-regulated entry of TH-17 cells into the CNS through the choroid plexus is required for the initiation of EAE. Nat Immunol 2009, 10: 514–523. doi:10.1038/ni.1716 10.1038/ni.1716View ArticlePubMedGoogle Scholar
- Veldhoen M, Hocking RJ, Atkins CJ, Locksley RM, Stockinger B: TGFbeta in the context of an inflammatory cytokine milieu supports de novo differentiation of IL-17-producing T cells. Immunity 2006, 24: 179–189. doi:10.1016/j.immuni.2006.01.001 10.1016/j.immuni.2006.01.001View ArticlePubMedGoogle Scholar
- Mangan PR, Harrington LE, O’quinn DB, Helms WS, Bullard DC, Elson CO, Hatton RD, Wahl SM, Schoeb TR, Weaver CT: Transforming growth factor-beta induces development of the T(H)17 lineage. Nature 2006, 441: 231–234. doi:10.1038/nature04754 10.1038/nature04754View ArticlePubMedGoogle Scholar
- Zhang N, Bevan MJ: Transforming growth factor-β signaling controls the formation and maintenance of gut-resident memory T cells by regulating migration and retention. Immunity 2013, 39: 687–696. doi:10.1016/j.immuni.2013.08.019 10.1016/j.immuni.2013.08.019View ArticlePubMedPubMed CentralGoogle Scholar
- Ifergan I, Kebir H, Alvarez JI, Marceau G, Bernard M, Bourbonnière L, Poirier J, Duquette P, Talbot PJ, Arbour N, Prat A: Central nervous system recruitment of effector memory CD8+ T lymphocytes during neuroinflammation is dependent on α4 integrin. Brain 2011, 134: 3560–3577. doi:10.1093/brain/awr268 10.1093/brain/awr268View ArticlePubMedGoogle Scholar
- Oxenius A, Bachmann MF, Zinkernagel RM, Hengartner H: Virus-specific major MHC class II-restricted TCR-transgenic mice: effects on humoral and cellular immune responses after viral infection. Eur J Immunol 1998, 28: 390–400. 10.1002/(SICI)1521-4141(199801)28:01<390::AID-IMMU390>3.0.CO;2-OView ArticlePubMedGoogle Scholar
- Laurence A, Tato CM, Davidson TS, Kanno Y, Chen Z, Yao Z, Blank RB, Meylan F, Siegel R, Hennighausen L, Shevach EM, O'Shea JJ: Interleukin-2 signaling via STAT5 constrains T helper 17 cell generation. Immunity 2007, 26: 371–381. doi:10.1016/j.immuni.2007.02.009 10.1016/j.immuni.2007.02.009View ArticlePubMedGoogle Scholar
- Brown DM, Kamperschroer C, Dilzer AM, Roberts DM, Swain SL: IL-2 and antigen dose differentially regulate perforin- and FasL-mediated cytolytic activity in antigen specific CD4+ T cells. Cell Immunol 2009, 257: 69–79. doi:10.1016/j.cellimm.2009.03.002 10.1016/j.cellimm.2009.03.002View ArticlePubMedPubMed CentralGoogle Scholar
- Pipkin ME, Sacks JA, Cruz-Guilloty F, Lichtenheld MG, Bevan MJ, Rao A: Interleukin-2 and inflammation induce distinct transcriptional programs that promote the differentiation of effector cytolytic T cells. Immunity 2010, 32: 79–90. doi:10.1016/j.immuni.2009.11.012 10.1016/j.immuni.2009.11.012View ArticlePubMedPubMed CentralGoogle Scholar
- McKinstry KK, Strutt TM, Buck A, Curtis JD, Dibble JP, Huston G, Tighe M, Hamada H, Sell S, Dutton RW, Swain SL: IL-10 deficiency unleashes an influenza-specific Th17 response and enhances survival against high-dose challenge. J Immunol 2009, 182: 7353–7363. doi:10.4049/jimmunol.0900657 10.4049/jimmunol.0900657View ArticlePubMedPubMed CentralGoogle Scholar
- Hou W, Kang HS, Kim BS: Th17 cells enhance viral persistence and inhibit T cell cytotoxicity in a model of chronic virus infection. J Exp Med 2009, 206: 313–328. doi:10.1084/jem.20082030 10.1084/jem.20082030View ArticlePubMedPubMed CentralGoogle Scholar
- Tate MD, Deng Y-M, Jones JE, Anderson GP, Brooks AG, Reading PC: Neutrophils ameliorate lung injury and the development of severe disease during influenza infection. J Immunol 2009, 183: 7441–7450. doi:10.4049/jimmunol.0902497 10.4049/jimmunol.0902497View ArticlePubMedGoogle Scholar
- Barker BR, Gladstone MN, Gillard GO, Panas MW, Letvin NL: Critical role for IL-21 in both primary and memory anti-viral CD8+ T-cell responses. Eur J Immunol 2010, 40: 3085–3096. doi:10.1002/eji.200939939 10.1002/eji.200939939View ArticlePubMedPubMed CentralGoogle Scholar
- Oyoshi MK, Elkhal A, Kumar L, Scott JE, Koduru S, He R, Leung DYM, Howell MD, Oettgen HC, Murphy GF, Geha RS: Vaccinia virus inoculation in sites of allergic skin inflammation elicits a vigorous cutaneous IL-17 response. Proc Natl Acad Sci U S A 2009, 106: 14954–14959. doi:10.1073/pnas.0904021106 10.1073/pnas.0904021106View ArticlePubMedPubMed CentralGoogle Scholar
- Suryawanshi A, Veiga-Parga T, Rajasagi NK, Reddy PBJ, Sehrawat S, Sharma S, Rouse BT: Role of IL-17 and Th17 cells in herpes simplex virus-induced corneal immunopathology. J Immunol 2011, 187: 1919–1930. doi:10.4049/jimmunol.1100736 10.4049/jimmunol.1100736View ArticlePubMedPubMed CentralGoogle Scholar
- Aly L, Yousef S, Schippling S, Jelcic I, Breiden P, Matschke J, Schulz R, Bofill-Mas S, Jones L, Demina V, Linnebank M, Ogg G, Girones R, Weber T, Sospedra M, Martin R: Central role of JC virus-specific CD4+ lymphocytes in progressive multi-focal leucoencephalopathy-immune reconstitution inflammatory syndrome. Brain 2011, 134: 2687–2702. doi:10.1093/brain/awr206 10.1093/brain/awr206View ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.